Abstract
First generation dendron bis-1,2-(4-acetylphenylethynyl)-4,5-dimethoxybenzene with a photo cleavable linkage to (t-butyloxycarbonyl-γ-aminobutyric acid (t-Boc-GABA) was synthesized for photo release study to apply for drug delivery. Both the divergent method from the core, 1,2- dimethoxybenzene and the convergent method from p-hydroxyacetophenone were not successful to generate the final dendron product. The dendron with caged GABA was successfully synthesized via the convergent method by attaching the model drug GABA on p-hydroxyacetophenone before the final Sonogashira coupling on 1,2-dimethoxybenzene according to the modified convergent method.
Keywords: Phototrigger, dendrimer, dendron, drug delivery, GABA, convergent method.
Graphical Abstract
(b) Dufès, C.; Uchegbu, I.F.; Schätzlein, A.G. Adv. Drug Deliv. Rev., 2005, 57, 2177-2202.
(c) Tripathy, D.K. J. Appl. Pharm. Sci., 2013, 3, 142-149.
(d) Allen, T.M. Cullis, P.R. Science, 2004, 19(303), 1818-1822.
(b) Liu, M.; Fréchet, M.J. Pharm. Sci. Technol. Today, 1999, 2, 393-401.
(c) Esfand, R.; Tomalia, D.A. Drug Discov. Today, 2001, 6, 427-436.
(b) Givens, R.S.; Conrad, G.P. II; Yousef, A.; Lee, J.I.In: CRC Handbook of Organic Photochemistry and Phtobiology; Horspool, W.; Lenci, F., Eds.; CRC press: Boca Raton, London, New York, Washington D.C., 2003, pp. 69.1-69.46.
(c) Brieke, C.; Rohrbach, F.; Gottschalk, A.; Mayer, G.; Heckel, A. Angew. Chem. Int. Ed., 2012, 51, 8447-8476.
(d) Klán, P.; Šolomek, T.; Bochet, C.G.; Blanc, A.; Givens, R.S.; Rubina, M.; Popik, V.; Kostikov, A.; Wirz, J. Chem. Rev., 2013, 113, 119-191.
(b) Maurice, R.; Givens, R.S. Wiley & Sons: New York; , 2005, p. ISBN: 978-3-527-60554-5..
(c) Givens, R.S.; Weber, J.F.W.; Conrad, II, P.G.; Orosz, G.; Donalhue, S.L.; Thayer, S.A. J. Am. Chem. Soc., 2000, 122, 2687-2697.
(b) Chennoufi, R.; Bougherara, H.; Gagey-Eilstein, N.; Dumat, B.; Henry, E.; Subra, F.; Bury-Mne, S.; Mahuteau-Betzer, F.; Tauc, P.; Teulade-Fichou, M.; Deprez, E. Sci. Rep., 2016, 6, 21458.
(c) McIlroy, S.P.; Clo, E.; Nikolajsen, L.; Frederiksen, P.K.; Nielsen, C.B.; Mikkelsen, K.V.; Gothelf, K.V.; Ogilby, P.R. J. Org. Chem., 2005, 70, 1134-1146.
(d) Biofrontera announces 12-month follow-up results of phase III trial evaluating Ameluz® for basal cell carcinoma [press release]. Leverkusen, Germany: Biofrontera AG; October 20, 2016.http://adhoc. pressetext.com/news/20161020019. Accessed January 26, 2018).